Zydus Lifesciences Ltd (BOM:532321)
₹ 964.4 -8.55 (-0.88%) Market Cap: 970.41 Bil Enterprise Value: 965.67 Bil PE Ratio: 22.61 PB Ratio: 4.45 GF Score: 97/100

Q2 2024 Zydus Lifesciences Ltd Earnings Call Transcript

Nov 07, 2023 / 10:30AM GMT
Release Date Price: ₹597.05 (+2.17%)
Ganesh Narayan Nayak
Zydus Lifesciences Limited - COO & Executive Director

(technical difficulty)

For today's call we have Dr. Sharvil Patel Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Arvind Bothra, Senior Vice President, Investor Relations; and Mr. Alok Garg Senior Vice President from the Managing Director's office. Now let me give you a broad overview of the developments during the quarter.

In terms of overall revenues, we registered stable growth of 9% during the quarter. Our Branded Formulations business in India grew in a single high digit after adjusting for impact of NLEM and partly affected by delay in the acute season. The U.S. Formulations business performed on expected lines, driven by a stable base business and supported by new introductions. Our Emerging Markets and Europe Formulations businesses continued growth momentum and delivered double-digit growth.

Our network of regulatory-compliant manufacturing facilities and a resilient supply chain serves as the backbone of our globally -- global business. We remain committed to extend our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot